Spots Global Cancer Trial Database for acute myeloid leukaemia
Every month we try and update this database with for acute myeloid leukaemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants. | NCT03217838 | Acute Myeloid L... | AZD2811 Azacitidine Venetoclax | 18 Years - 130 Years | AstraZeneca | |
| A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT | NCT04217278 | Acute Myeloid L... High-risk Myelo... | Vyxeos Fludarabine Busulphan Thiotepa Cytarabine | 18 Years - | University of Birmingham | |
| Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations | NCT02272478 | Acute Myeloid L... Myelodysplastic... | Arm A Mylotarg ... Arm B Vosaroxin... Arm D Small mol... Arm C DA V FLAG... Arm E CPX-351 (... Arm F DA V IDAC | 60 Years - | Cardiff University | |
| Transfusion Dependency at Diagnosis and Transfusion Intensity During Initial Chemotherapy Are Associated With Poorer Outcomes in Adult Acute Myeloid Leukaemia | NCT02844257 | Acute Myeloid L... | 15 Years - 83 Years | Hospices Civils de Lyon | ||
| Study of the Outcome of Patients With Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Receiving Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell Transplantation | NCT03659084 | Myeloid Leukemi... Myelodysplastic... | EXJADE | 18 Years - | Hospices Civils de Lyon | |
| Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT01716364 | Multiple Myelom... Acute Myeloid L... Myelodysplastic... | Anti-LeY- scFv-... | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) | NCT01147939 | Acute Myeloid L... | Elacytarabine Investigator's ... | 18 Years - | Clavis Pharma | |
| Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) | NCT01147939 | Acute Myeloid L... | Elacytarabine Investigator's ... | 18 Years - | Clavis Pharma | |
| Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers | NCT01240525 | Graft Versus Ho... Leukemia Lymphoma Myeloma Myelodysplastic... | CD4 DLI No DLI | 18 Years - 69 Years | University College, London | |
| Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants. | NCT03217838 | Acute Myeloid L... | AZD2811 Azacitidine Venetoclax | 18 Years - 130 Years | AstraZeneca | |
| Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old | NCT04687761 | Leukemia, Myelo... De Novo Age More 60yr | Azacitidine Venetoclax Quizartinib Cytarabine Venetoclax Quizartinib | 60 Years - | PETHEMA Foundation | |
| Reduction of Cord Blood Transplantation Toxicity in Patients With Acute Myeloid Leukemia | NCT00797758 | Acute Myeloid L... | Cord blood tran... | 4 Years - 65 Years | Assistance Publique - Hôpitaux de Paris | |
| Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML) | NCT01422603 | Acute Myeloid L... Myelodysplasia | Clofarabine Clofarabine | 18 Years - | University Hospital Southampton NHS Foundation Trust | |
| Lentivirus Transduced Acute Myeloid Leukaemia Blasts Expressing B7.1 (CD80) and IL-2 | NCT00718250 | Leukemia, Myelo... | RFUSIN2-AML1 Donor leukocyte... RFUSIN2-AML1 an... RFUSIN2-AML1 an... | 18 Years - | King's College Hospital NHS Trust | |
| Reduction of Cord Blood Transplantation Toxicity in Patients With Acute Myeloid Leukemia | NCT00797758 | Acute Myeloid L... | Cord blood tran... | 4 Years - 65 Years | Assistance Publique - Hôpitaux de Paris | |
| An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML) | NCT01019161 | Acute Myeloid L... | AZD1152 C14 AZD1152 | 18 Years - | AstraZeneca | |
| Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML) | NCT06326697 | Acute Myeloid L... | Azacitidine Onureg | 18 Years - | Hikma Pharmaceuticals LLC | |
| Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML) | NCT01422603 | Acute Myeloid L... Myelodysplasia | Clofarabine Clofarabine | 18 Years - | University Hospital Southampton NHS Foundation Trust | |
| Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) | NCT01147939 | Acute Myeloid L... | Elacytarabine Investigator's ... | 18 Years - | Clavis Pharma | |
| Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers | NCT01597219 | Hodgkin's Lymph... Non-Hodgkin's L... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Chronic Myeloid... Chronic Lymphoc... Acquired Bone M... Other Haematolo... | Reduced intensi... Myeloablative h... | 16 Years - 70 Years | University College, London | |
| Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML) | NCT01063660 | Acute Myeloid L... | Treosulfan | 18 Years - 60 Years | medac GmbH | |
| MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | NCT06345365 | Acute Myeloid L... | mitoxantrone li... Daunorubicin,Ar... | 18 Years - 75 Years | Zhongnan Hospital | |
| Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old | NCT04687761 | Leukemia, Myelo... De Novo Age More 60yr | Azacitidine Venetoclax Quizartinib Cytarabine Venetoclax Quizartinib | 60 Years - | PETHEMA Foundation | |
| Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML) | NCT00530699 | Acute Myeloid L... | AZD1152 | 20 Years - | AstraZeneca | |
| Intermittent Liposomal Amphotericin B Primary Prophylaxis | NCT00451711 | Acute Myeloid L... | Liposomal ampho... | 18 Years - 80 Years | Bayside Health | |
| A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. | NCT01236144 | Acute Myeloid L... High Risk Myelo... | Plerixafor AC220 Ganetespib | 60 Years - | Cardiff University | |
| Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers | NCT01240525 | Graft Versus Ho... Leukemia Lymphoma Myeloma Myelodysplastic... | CD4 DLI No DLI | 18 Years - 69 Years | University College, London | |
| Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants. | NCT03217838 | Acute Myeloid L... | AZD2811 Azacitidine Venetoclax | 18 Years - 130 Years | AstraZeneca | |
| Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML<60a | NCT01414231 | Acute Myeloid L... | Cytarabine | 18 Years - 60 Years | University of Leipzig | |
| Lentivirus Transduced Acute Myeloid Leukaemia Blasts Expressing B7.1 (CD80) and IL-2 | NCT00718250 | Leukemia, Myelo... | RFUSIN2-AML1 Donor leukocyte... RFUSIN2-AML1 an... RFUSIN2-AML1 an... | 18 Years - | King's College Hospital NHS Trust | |
| A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia | NCT05712278 | Acute Myeloid L... | SAR445419 fludarabine cytarabine | 18 Years - | Sanofi | |
| A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. | NCT01236144 | Acute Myeloid L... High Risk Myelo... | Plerixafor AC220 Ganetespib | 60 Years - | Cardiff University | |
| Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia | NCT04106076 | Acute Myeloid L... | UCART123 | 18 Years - 65 Years | Cellectis S.A. | |
| Transfusion Dependency at Diagnosis and Transfusion Intensity During Initial Chemotherapy Are Associated With Poorer Outcomes in Adult Acute Myeloid Leukaemia | NCT02844257 | Acute Myeloid L... | 15 Years - 83 Years | Hospices Civils de Lyon |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
